Anti-VEGF

Editor(s): Bandello, F. (Milan)
Battaglia Parodi, M. (Milan)
Augustin, A.J. (Karlsruhe)
Iacono, P. (Rome)
Schlingemann, R.O. (Amsterdam)
Schmidt-Erfurth, U. (Vienna)
Verbraak, F.D. (Amsterdam)
 

Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration

Schmidt-Erfurth U. · Pollreisz A. · Mitsch C. · Bolz M.

Author affiliations

Department of Ophthalmology and Optometry, Medical University Vienna, Vienna, Austria

Related Articles for ""
Bandello F, Battaglia Parodi M (eds): Anti-VEGF. Dev Ophthalmol. Basel, Karger, 2010, vol 46, pp 21–38
https://doi.org/10.1159/000320007

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: August 10, 2010
Cover Date: 2010

Number of Print Pages: 18
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9529-2 (Print)
eISBN: 978-3-8055-9530-8 (Online)

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in adults aged over 50 years in developed countries. Until recently, argon laser photocoagulation and photo-dynamic therapy (PDT) were the only treatments available for the neovascular form of AMD. The introduction of new intravitreally injectable inhibitors of vascular endothelial growth factor (VEGF) revolutionized the management of the wet form. Pegaptanib was the first anti-VEGF agent to be approved by the US Food and Drug Administration (FDA) for use in neovascular AMD. The VISION study showed that patients receiving pegaptanib lost vision in a smaller rate than those treated with conventional care. Bevacizumab is a full-length recombinant humanized monoclonal antibody which binds to all isoforms of VEGF-A. It is licensed for the intravenous administration for the treatment of malignant solid tumors and is available for off-label use in the treatment of AMD-related CNV. Numerous retrospective studies have shown beneficial effects of bevacizumab in patients with neovascular AMD. Ranibizumab is a recombinant, humanized antibody antigen-binding fragment (Fab) that binds to all known active forms of VEGF-A. The US FDA approved ranibizumab for treatment of all subtypes of choroidal neovascularization secondary to AMD. VEGF trap is a pharmacologically engineered protein that binds VEGF with higher affinity than pegaptanib or ranibizumab and thus prevents VEGF binding to its cellular receptor offering a theoretically longer interval between necessary treatments. A number of studies have shown that OCT imaging allows identification of functionally relevant factors like subretinal fluid or retinal thickness, which are important for the establishment of optimized individual dosing regimen during anti-angiogenesis therapies.

© 2010 S. Karger AG, Basel



Related Articles:

References

  1. VanNewkirk MR, Nanjan MB, Wang JJ, et al: The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000;107:1593-1600
  2. Mitchell P, Smith W, Attebo K, Wang JJ: Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-1460
  3. Buch H, Nielsen NV, Vinding T, et al: Fourteen-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology 2005;112:787-798
  4. Klein R, Klein BE, Knudtson MD, et al: Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007;114:253-262
  5. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29
  6. Reynolds R, Hartnett ME, Atkinson JP, et al: Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009;50:5818-5827
  7. Morohoshi K, Goodwin AM, Ohbayashi M, Ono SJ: Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J Autoimmun 2009;33:247-254
  8. Okemefuna Al, Nan R, Miller A, et al: Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem 2010;285:1053-1065
  9. Schmidt-Erfurth U, Pruente C: Management of neovascular age-related macular degeneration. Prog Retin Eye Res 2007;26:437-451
  10. Schmidt-Erfurth U, Richard G, Augustin A, et al: Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007;85:486-494
  11. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676
  12. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395
  13. Ishibashi T, Hata Y, Yoshikawa H, et al: Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-167
  14. Kvanta A: Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006;84:282-288
  15. Petrova TV, Makinen T, Alitalo K: Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999;253:117-130
  16. Frank RN, Amin RH, Eliott D, et al: Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393-403
  17. Kvanta A, Algvere PV, Berglin L, Seregard S: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934
  18. Kliffen M, Sharma HS, Mooy CM, et al: Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162
  19. Shima DT, Adamis AP, Ferrara N, et al: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor as the mitogen. Mol Med 1995;1:182-193
  20. Funk M, Karl D, Georgopoulos M, et al: Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399
  21. Waheed NK, Miller JW: Aptamers, intramers, and vascular endothelial growth factor. Int Ophthalmol Clin 2004;44:11-22
  22. Famulok M, Mayer G, Blind M: Nucleic acid aptamers - from selection in vitro to applications in vivo. Ace Chem Res 2000;33:591-599
  23. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-822
  24. Schachat AP: New treatments for age-related macular degeneration. Ophthalmology 2005;112:531-532
  25. Ruckman J, Green LS, Beeson J, et al: 2'-Fluoro-pyrimidine RNA-based aptamers to the 165-amino-acid form of vascular endothelial growth factor (VEGF-165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7 encoded domain. J Biol Chem 1998;273:20556-20567
  26. Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152
  27. Eyetech Study Group: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-986
  28. Gragoudas ES, Adamis AP, Cunningham ET, Jr, et al: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816
  29. Spaide R: New treatments for AMD. Ophthalmology 2006;113:160-161
  30. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
  31. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599
  32. Adding a humanized antibody to vascular endothelial growth factor (bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 2003;3:85-88
  33. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65
  34. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
  35. Mordenti J, Cuthbertson RA, Ferrara N, et al: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-544
  36. Heiduschka P, Fietz H, Hofmeister S, et al: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823
  37. Shahar J, Avery RL, Heilweil G, et al: Electro-physiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269
  38. Michels S, Rosenfeld PJ, Puliafito CA, et al: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration 12-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047
  39. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: 24-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002;e1-12
  40. Geitzenauer W, Michels S, Prager F, et al: Comparison of 2.5 and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: 24-week results of an uncontrolled, prospective cohort study. Retina 2008;28:1375-1386
  41. Bolz M, Michels S, Geitzenauer W, et al: Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 2007;91:785-789
  42. Rosenfeld PJ, Fung AE, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339
  43. Weigert G, Michels S, Sacu S, et al: Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-360
  44. Hahn R, Sacu S, Michels S, et al: Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration (in German). Ophthalmologe 2007;104:588-593
  45. Costa RA, Jorge R, Calucci D, et al: Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578
  46. Kiss C, Michels S, Prager F, et al: Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-881
  47. Leydolt C, Michels S, Prager F, et al: Effect of intravitreal bevacizumab (Avastin®) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6-and 12-month results. Acta Ophthalmol 2009;Epub ahead of print
  48. Sacu S, Michels S, Prager F, et al: Randomised clinical trial of intravitreal Avastin vs. photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 2009;23:2223-2227
  49. Spaide RF, Laud K, Fine HF, et al: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390
  50. Rich RM, Rosenfeld PJ, Puliafito CA, et al: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511
  51. Avery RL, Pieramici DJ, Rabena MD, et al: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363372.e5.
  52. Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349
  53. Artunay O, Yuzbasioglu E, Rasier R, et al: Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:2187-2193
  54. Sato T, Emi K, Ikeda T, et al: Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010;117:512516.e1-2.
  55. Yenerel NM, Dinc UA, Gorgun E: A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24:362-363
  56. Yamashiro K, Tsujikawa A, Miyamoto K, et al: Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010;30:485-490
  57. Georgopoulos M, Polak K, Prager F, et al: Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-462
  58. Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431
  59. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444
  60. TAP Report 1: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials. Arch Ophthalmol 1999;117:1329-1345
  61. TAP Report 2: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials. Arch Ophthalmol 2001;119:198-207
  62. Andrew NA, Lisa T, Carol YC, Angele S: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862874.e3.
  63. Mitchell P, Korobelnik JF, Lanzetta P, et al: Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2009;20:20
  64. Holz FG, Korobelnik JF, Lanzetta P, et al: The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2009;51:405-412
  65. Schmidt-Erfurth U, Eldem B, Guymer R, et al: on behalf of the EXCITE Study Group: Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration. Ophthalmology 2010;in press
  66. Schmidt-Erfurth U: Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010;9:149-165
  67. Carl DR, David MB, Prema A, et al: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239248.e5.
  68. Lalwani GA, Rosenfeld PJ, Fung AE, et al: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:4358.e1.
  69. Quan Dong N, Syed Mahmood S, Gulnar H, et al: A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522.e1-14.
  70. Do DV: Antiangiogenic approaches to age-related macular degeneration in the future. Ophthalmology 2009;116:(suppl 1)S24-S6
  71. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-4480
  72. Kiss CG, Simader C, Michels S, Schmidt-Erfurth U: Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study. Br J Ophthalmol 2008;92:1620-1627
  73. Schmidt-Erfurth U, Wolf S: Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008;92:1628-1635
  74. Srinivasan VJ, Wojtkowski M, Witkin AJ, et al: High-definition and three-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:2054.e1-14
  75. Golbaz I, Ahlers C, Goesseringer N, et al: Automatic and manual segmentation of healthy retinas using high-definition optical coherence tomography. Acta Ophthalmol 2009;Epub ahead of print
  76. Mylonas G, Ahlers C, Malamos P, et al: Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol 2009;93:1453-1460
  77. Gotzinger E, Pircher M, Baumann B, et al: Three-dimensional polarization sensitive OCT imaging and interactive display of the human retina. Opt Express 2009;17:4151-4165
  78. Ahlers C, Schmidt-Erfurth U: Three-dimensional high resolution OCT imaging of macular pathology. Opt Express 2009;17:4037-4045
  79. Ahlers C, Gotzinger E, Pircher M, et al: Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51:2149-2157
  80. Puliafito CA, Hee MR, Lin CP, et al: Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217-229
  81. Pieroni CG, Witkin AJ, Ko TH, et al: Ultrahigh resolution optical coherence tomography in non-exu-dative age-related macular degeneration. Br J Ophthalmol 2006;90:191-197
  82. Malamos P, Sacu S, Georgopoulos M, et al: Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci 2009;50:4926-4933
  83. Golbaz I, Ahlers C, Schutze C, et al: Influence of antiangiogenetic therapy on retinal thickness values in age-related macular degeneration (in German). Ophthalmologe 2009;106:1103-1110
  84. Einwallner E, Ahlers C, Golbaz I, et al: Neovascular age-related macular degeneration under anti-angiogenic therapy: subretinal fluid is a relevant prognostic parameter (in German). Ophthalmologe 2010;107:158-164
  85. Andreoli CM, Miller JW: Antivascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-508
  86. Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637
  87. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444
  88. Kaiser PK, Blodi BA, Shapiro H, Acharya NR: Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-1875
  89. Regillo CD, Brown DM, Abraham P, et al: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248
  90. Shah AR, Del Priore LV: Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 2009;93:1027-1032
  91. Witkin AJ, Vuong LN, Srinivasan VJ, et al: High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmology 2009;116:956-963
  92. Framme C, Panagakis G, Birngruber R: Effects on choroidal neovascularization after anti-VEGF upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51:1671-1676
  93. Bolz M, Simader C, Ritter M, et al: Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:185-189
  94. Ahlers C, Golbaz I, Stock G, et al: Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 2008;115:e39-e46
  95. Kiss CG, Geitzenauer W, Simader C, et al: Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376-2383
  96. Bakri SJ, Kitzmann AS: Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 2007;143:505-507
  97. Kiss C, Michels S, Prager F, et al: Retinal pigment epithelium tears following intravitreal ranibizumab therapy. Acta Ophthalmol Scand 2007;85:902-903
  98. Chan CKM, Meyer CHM, et al: Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007;27:541-551
  99. Apte RS: Retinal pigment epithelial tear after intravitreal ranibizumab for subfoveal CNV secondary to AMD. Int Ophthalmol 2007;27:59-61

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: August 10, 2010
Cover Date: 2010

Number of Print Pages: 18
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9529-2 (Print)
eISBN: 978-3-8055-9530-8 (Online)

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

Table of Contents

Article

Recommend This
TOP